OMEICOS Therapeutics
Berlin
About OMEICOS Therapeutics
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $37.3M
- Funding stage: Late Stage Venture
- Last round: Series C (Nov 2018)
- Website: omeicos.com
- Phone: +49 (0)30 9489 4810
Industries & Categories
Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/omeicos-therapeutics-30475 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.